MILLENNIUM PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2003-07-11
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT00064610
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Columbia-Presbyterian Hospital, New York, New York, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic Syndrome
- First Posted Date
- 2003-07-10
- Last Posted Date
- 2009-03-24
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00064584
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE
- Conditions
- Multiple Myeloma
- First Posted Date
- 2003-07-08
- Last Posted Date
- 2007-02-14
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT00063791
- Locations
- 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸Michael Meshad, Oncology Center, Mobile, Alabama, United States
🇺🇸Toledo Clinic, Toledo, Ohio, United States
VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- First Posted Date
- 2003-07-04
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT00063713
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸UCLA School of Medicine, Los Angeles, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-01-22
- Last Posted Date
- 2007-03-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT00052000
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸The Sidney Kimmel Comprehensive Cancer Center @ Johns Hopkins, Baltimore, Maryland, United States
Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2003-01-22
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT00051974
- Locations
- 🇺🇸
Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Medical Center Thoracic Malignancy, Los Angeles, California, United States
🇺🇸Atlanta VAMC, Decatur, Georgia, United States
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma
- Conditions
- Colorectal Carcinoma
- First Posted Date
- 2003-01-22
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 175
- Registration Number
- NCT00051987
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸California Cancer Center, Greenbrae, California, United States
🇺🇸St. Lukes Rossevelt Hospital, New York, New York, United States
PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2002-10-30
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 620
- Registration Number
- NCT00048230
- Locations
- 🇺🇸
Kaiser Permanente Oncology Clinical Trials, Vallejo, California, United States
🇺🇸Texas Oncology at Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸Western Pennsylvania Hospital, Dept. of Human Oncology, Pittsburgh, Pennsylvania, United States